Clinical Advances in Hematology & Oncology

March 2014, Volume 12, Issue 3

John D. Hainsworth, MD, has modified the commentary he wrote for the December 2013 issue of Clinical Advances in Hematology & Oncology, “Evolving understanding and management of poorly differentiated neuroendocrine tumors.” This commentary appeared with “Metastatic pancreatic poorly differentiated neuroendocrine carcinoma: current treatment considerations” by Steven Sorscher, MD. The final paragraph of the commentary now reads as follows:

No substantial improvements in the therapy of small cell lung cancer or other PDNETs have occurred in over 20 years. To improve the therapy of these neoplasms, critical “driver” molecular abnormalities must be identified and exploited. A number of candidates are currently in early clinical testing. Owing to the similar spectrum of molecular abnormalities, it is likely that new targeted drugs that are highly effective against small cell lung cancer will also have activity in the treatment of other PDNETs.

Readers are advised to download the corrected online version at